Please assess the completion status of the following clinical trial:

Trial Title: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis and main criteria for inclusion and exclusion:~The following are the main inclusion criteria:~* Adults able to provide informed consent.~* Documented characteristically benign adrenal nodule, with diameter ≤ 4 cm, homogenous texture, and non-contrast computerized tomography ≤ 20 HU attenuation or proven to be non malignant.~* Diagnosis of diabetes mellitus, pre-diabetes or impaired glucose tolerance, either untreated or on stable standard of care treatment, based on at least one of:~  * HbA1c ≥ 5.7% but not \> 9.5%~ * 2-hour glucose level ≥ 7.8 mmol (140 mg/dL) on a 75 g OGTT~* At least one additional documented cortisol-related morbidities, either untreated or on stable standard of care treatment:~  * hypercholesterolemia with total cholesterol \> 3.9 mM (150 mg/dL);~ * hypertriglyceridemia with triglycerides \> 2.3 mM (200 mg/dL);~ * osteopenia with bone densitometry Z-score \< -2.0 or T-score \< -1.0;~ * history or evidence of minimally traumatic or osteoporotic fracture; or~ * hypertension with resting supine blood pressure \> 130 but \< 180 mmHg systolic or \> 85 but \< 120 mmHg diastolic.~* Poorly suppressible hypercortisolemia:~  * Morning serum cortisol \> 50 nM (1.8 mcg/dL) after a 1 mg ONDST.~ * Subjects with dexamethasone \< 3.3 nmol/L (130 ng/dL) will undergo a high-dose (8 mg) ONDST.~ * Subjects who take estrogen-containing medicines will be evaluated based on free cortisol \> 2.2 nM (80 ng/dL).~ * For subjects with morning serum cortisol \> 138 nM (5.0 mcg/dL) after ONDST, the Investigator will assess for adrenal Cushing's syndrome.~Exclusion Criteria:~* Diagnosis of ACTH-dependent Cushing's syndrome, pheochromocytoma, aldosteronoma, adrenocortical carcinoma, or congenital adrenal hyperplasia, or other malignancy associated hypercortisolism including history of adrenal carcinoma.~* History of adrenalectomy or planned adrenalectomy within 4 months after randomization.~* Exogenous hypercortisolism.~* Uncontrolled, clinically significant hypo- or hyperthyroidism.~* History of idiopathic thrombocytopenia.~* Moderately impaired renal function (estimated glomerular filtration rate \< 60 mL/min/1.73m2).~* History of cancer (other than non-melanoma skin, thyroid, or early-stage prostate cancer) within 3 years.~* Any major surgery, or significant post-operative sequelae, within 1 month prior to informed consent or planned during the trial.~* Pregnant or lactating.~* Positive test for severe acute respiratory syndrome coronavirus 2 infection within 4 weeks, or hospitalization for Coronavirus disease 2019 within 6 months, prior to randomization.~* Any other current or prior medical condition expected to interfere with the conduct of the trial or the evaluation of its results.~* Participation in any clinical trial within 3 months prior to the first dose of study drug, or longer depending on half-life of the investigational therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SPI-62 dose (Type: EXPERIMENTAL): 2mg dose level of SPI-62. Active drug by mouth.

Based on this trial design, predict the completion outcome and termination type (if applicable).